FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX)

Historical Holders from Q1 2020 to Q3 2025

Type / Class
Equity / GENOMIC ADV ETF
Symbol
HELX
Price per share
$36.98
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
14,268
Total reported value
$439,474
% of total 13F portfolios
0%
Share change
-78,365
Value change
-$2,212,623
Number of holders
5
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
As of 30 Sep 2025, FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX) has 5 institutional shareholders filing 13F forms. They hold 14,268 shares. .

Institutional Holders of FRANKLIN TEMPLETON ETF TR - GENOMIC ADV ETF (HELX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 14,268 $439,474 -$2,212,623 $30.95 5
2025 Q2 92,633 $2,567,033 +$309,093 $27.71 8
2025 Q1 81,687 $2,205,710 -$638,047 $27.00 8
2024 Q4 103,042 $2,973,230 +$1,597,396 $28.85 9
2024 Q3 47,673 $1,545,263 -$962,872 $32.41 5
2024 Q2 78,142 $2,475,997 -$568,499 $31.68 7
2024 Q1 95,001 $3,112,326 -$1,496,883 $32.76 10
2023 Q4 140,810 $4,290,918 +$3,127,648 $30.47 9
2023 Q3 38,719 $1,096,611 -$1,319,967 $28.34 7
2023 Q2 82,302 $2,487,571 -$37,724 $30.23 7
2023 Q1 38,766 $1,177,374 -$121,596 $30.38 6
2022 Q4 42,786 $1,289,178 +$61,903 $30.13 9
2022 Q3 40,724 $1,207,000 +$316,642 $29.63 9
2022 Q2 30,030 $962,000 -$80,086 $32.04 7
2022 Q1 31,478 $1,163,504 -$4,705,793 $36.95 8
2021 Q4 155,206 $7,526,219 -$6,279,456 $48.42 11
2021 Q3 273,604 $14,313,683 +$10,169,153 $52.30 10
2021 Q2 79,619 $4,122,950 -$98,464 $51.79 9
2021 Q1 81,510 $3,532,751 +$1,386,139 $43.35 8
2020 Q4 43,257 $1,916,000 +$761,000 $44.29 5
2020 Q3 28,241 $991,000 -$1,290,500 $35.10 5
2020 Q2 65,000 $2,229,000 -$342,923 $34.29 1
2020 Q1 75,000 $1,678,000 +$1,677,998 $22.37 1